ERBB2 and non-small cell lung carcinoma: In addition, it was approved as a Grade III recommendation for HER2-mutant NSCLC treatment in China and was recently elevated to a Grade II recommendation for the same indication, though not in the adjuvant setting (Yingge et al., 2023; CSCO, 2024).